Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

NUT midline carcinoma


NUT midline carcinoma, a squamous cell carcinoma, is one of the most aggressive human cancers, and there is a desperate need for effective therapies for patients with this disease. Will the new bromodomain and extra terminal (BET) inhibitors prove to be one such treatment for this rare and enigmatic cancer?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: A model of how BRD4–NUT might block differentiation.


  1. 1

    French, C. A. et al. BRD-NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells. Oncogene 27, 2237–2242 (2008).

    CAS  Article  Google Scholar 

  2. 2

    Bauer, D. et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin. Cancer Res. 18, 5773–5779 (2012).

    Article  Google Scholar 

  3. 3

    Haack, H. et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am. J. Surg. Pathol. 33, 984–991 (2009).

    Article  Google Scholar 

  4. 4

    Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

    CAS  Article  Google Scholar 

  5. 5

    Reynoird, N. et al. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 29, 2943–2952 (2010).

    CAS  Article  Google Scholar 

  6. 6

    Grayson, A. R. et al. MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. Oncogene (2013).

  7. 7

    Schwartz, B. E. et al. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 71, 2686–2696 (2011).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Christopher French.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

French, C. NUT midline carcinoma. Nat Rev Cancer 14, 149–150 (2014).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing